1. Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation 
Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly Maloy, Dick Chung, Hugo Castro-Malaspina, Sergio A. Giralt, Esperanza Papadopoulos, Miguel-Angel Perales, Ann A. Jakubowski, Genovefa A. Papanicolaou 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 8, Pages (August 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Cumulative incidence of CMV viremia (A) and CMV disease (B) after HCT for CMV R+/D+, R+/D−, R−/D+, and R−/D− transplant recipients. (A) The 180-day incidence of CMV viremia is shown by CMV R/D serostatus. R+/D+ patients had higher 180-day incidence compared to R+/D− (P = .02); none of the R−/D+ and R−/D− patients developed CMV viremia. (B) The 365-day cumulative incidence of CMV disease is shown by CMV R/D serostatus. One-year post-HCT incidence of CMV disease was similar for R+/D+ and R+/D− (P = .19).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Kaplan-Meier analysis of overall survival (OS) at 365 days for the entire cohort (n = 213): (A) patients with CMV viremia versus no viremia, (B) CMV persistent viremia versus no persistent viremia, and (C) CMV recipient (R)/Donor (D) serostatus. All 213 patients were included in each survival analysis. One-year OS was compared by the log-rank test between (A) patients with (solid line) and without CMV viremia (dotted line). (B) Persistent viremia (solid line) versus nonpersistent viremia (dotted line) and (C) By CMV R/D serostatus. Differences of OS between different groups were not statistically significant.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions